Ranibizumab and laser — Competitive Intelligence Brief

Ranibizumab and laser (Ranibizumab and laser) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation. Area: Ophthalmology.

marketed VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation VEGF-A Ophthalmology Small molecule

Target snapshot

Ranibizumab and laser (Ranibizumab and laser) — Fukushima Medical University. Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina, while laser photocoagulation thermally destroys abnormal retinal tissue.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ranibizumab and laser TARGET	Ranibizumab and laser	Fukushima Medical University	marketed	VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation	VEGF-A
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Syfovre™	Syfovre™	Hoffmann-La Roche	marketed	Anti-VEGF aptamer	VEGF-A
Intravitreal Ranibizumabe	Intravitreal Ranibizumabe	University of Sao Paulo	marketed	VEGF-A inhibitor; monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
Rescue Intravitreal Aflibercept Injection	Rescue Intravitreal Aflibercept Injection	Southeast Retina Center, Georgia	marketed	VEGF inhibitor / Recombinant fusion protein	VEGF-A, VEGF-B, PlGF (placental growth factor)
Ziv aflibercept	Ziv aflibercept	Marashi Eye Clinic	marketed	VEGF inhibitor / Antiangiogenic agent	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Aflibercept and ranibizumab	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation class)

1. Fukushima Medical University · 1 drug in this class